Compare Stocks

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACET Adicet Bio	$2.03 -11.0%	$2.39	$1.10 ▼ $7.50	$166.39M	1.88	1.58 million shs	929,963 shs
CTIC CTI BioPharma	$9.09	$9.06	$4.01 ▼ $9.10	$1.20B	0.83	4.50 million shs	N/A
KNTE Kinnate Biopharma	$2.65 -0.4%	$2.56	$1.04 ▼ $7.18	$125.13M	1.38	418,678 shs	2.81 million shs
VRNA Verona Pharma	$16.10 -1.8%	$16.53	$11.83 ▼ $23.81	$1.30B	0.4	498,215 shs	489,991 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACET Adicet Bio	-10.79%	-9.60%	-0.25%	-17.01%	-66.97%
CTIC CTI BioPharma	0.00%	0.00%	0.00%	0.00%	+77.54%
KNTE Kinnate Biopharma	0.00%	0.00%	+3.92%	+10.88%	-20.66%
VRNA Verona Pharma	-1.83%	-0.43%	+5.23%	-6.23%	-28.00%

The “Perfect Storm” for Gold (Ad)

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACET Adicet Bio	2.7896 of 5 stars	3.3	1.0	0.0	3.3	5.0	0.6
CTIC CTI BioPharma	0.0451 of 5 stars	1.0	0.0	0.0	0.6	1.7	0.6
KNTE Kinnate Biopharma	4.3836 of 5 stars	3.1	5.0	4.7	0.6	3.3	1.3
VRNA Verona Pharma	1.1017 of 5 stars	3.5	0.0	0.0	2.0	1.7	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACET Adicet Bio	2.63	Moderate Buy	$12.83	533.74% Upside
CTIC CTI BioPharma	2.00	Hold	$9.00	-0.99% Downside
KNTE Kinnate Biopharma	2.17	Hold	$11.72	342.19% Upside
VRNA Verona Pharma	3.00	Buy	$33.60	108.70% Upside

Current Analyst Ratings

Latest VRNA, CTIC, ACET, and KNTE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/16/2024	VRNA Verona Pharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$31.00 ➝ $36.00
4/2/2024	ACET Adicet Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
3/20/2024	ACET Adicet Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
3/20/2024	ACET Adicet Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$5.00
3/20/2024	ACET Adicet Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00
3/4/2024	VRNA Verona Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00
3/1/2024	VRNA Verona Pharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$33.00
2/26/2024	KNTE Kinnate Biopharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$2.59
2/16/2024	KNTE Kinnate Biopharma	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
2/5/2024	ACET Adicet Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$15.00
2/2/2024	ACET Adicet Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$26.00 ➝ $10.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACET Adicet Bio	$24.99M	6.66	N/A	N/A	$2.43 per share	0.83
CTIC CTI BioPharma	$53M	22.62	N/A	N/A	($0.14) per share	-64.93
KNTE Kinnate Biopharma	N/A	N/A	N/A	N/A	$5.06 per share	N/A
VRNA Verona Pharma	$460K	2,828.70	N/A	N/A	$3.10 per share	5.19

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACET Adicet Bio	-$142.66M	-$3.32	N/A	N/A	N/A	N/A	-56.63%	-48.16%	5/14/2024 (Estimated)
CTIC CTI BioPharma	-$92.99M	-$0.58	N/A	26.74	N/A	-91.38%	N/A	-55.82%	N/A
KNTE Kinnate Biopharma	-$116.27M	-$2.78	N/A	N/A	N/A	N/A	-62.31%	-54.72%	5/9/2024 (Estimated)
VRNA Verona Pharma	-$54.37M	-$0.69	N/A	N/A	N/A	N/A	-20.47%	-17.72%	5/14/2024 (Estimated)

Latest VRNA, CTIC, ACET, and KNTE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/19/2024	Q4 2023	ACET Adicet Bio	-$0.72	-$0.69	+$0.03	-$0.69	$5.00 million	N/A
2/29/2024	Q4 2023	VRNA Verona Pharma	-$0.23	-$0.16	+$0.07	-$0.16	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACET Adicet Bio	N/A	N/A	N/A	N/A	N/A
CTIC CTI BioPharma	N/A	N/A	N/A	N/A	N/A
KNTE Kinnate Biopharma	N/A	N/A	N/A	N/A	N/A
VRNA Verona Pharma	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACET Adicet Bio	N/A	8.41	8.41
CTIC CTI BioPharma	N/A	1.27	1.26
KNTE Kinnate Biopharma	N/A	10.80	10.80
VRNA Verona Pharma	0.20	33.33	33.33

Ownership

Institutional Ownership

Company	Institutional Ownership
ACET Adicet Bio	83.89%
CTIC CTI BioPharma	91.45%
KNTE Kinnate Biopharma	80.89%
VRNA Verona Pharma	85.88%

Insider Ownership

Company	Insider Ownership
ACET Adicet Bio	29.50%
CTIC CTI BioPharma	7.61%
KNTE Kinnate Biopharma	41.70%
VRNA Verona Pharma	4.80%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ACET Adicet Bio	143	82.17 million	57.93 million	Optionable
CTIC CTI BioPharma	127	131.88 million	121.84 million	Optionable
KNTE Kinnate Biopharma	84	47.22 million	27.53 million	Optionable
VRNA Verona Pharma	79	80.82 million	76.94 million	Optionable

VRNA, CTIC, ACET, and KNTE Headlines

Source	Headline
	Verona Pharma (NASDAQ:VRNA) Price Target Increased to $36.00 by Analysts at Piper Sandler americanbankingnews.com - April 17 at 3:36 AM
	Verona Pharma (NASDAQ:VRNA) Trading 3.7% Higher After Analyst Upgrade americanbankingnews.com - April 17 at 1:08 AM
	Verona Pharma (NASDAQ:VRNA) Stock Price Up 3.7% on Analyst Upgrade marketbeat.com - April 16 at 10:36 AM
	Verona Pharma (NASDAQ:VRNA) PT Raised to $36.00 at Piper Sandler marketbeat.com - April 16 at 8:33 AM
	Verona Pharma (NASDAQ:VRNA) Shares Up 4.9% marketbeat.com - April 4 at 3:08 PM
	American Century Companies Inc. Purchases Shares of 280,126 Verona Pharma plc (NASDAQ:VRNA) marketbeat.com - March 28 at 4:07 AM
	Wellington Management Group LLP Acquires 164,268 Shares of Verona Pharma plc (NASDAQ:VRNA) marketbeat.com - March 19 at 4:54 AM
	VRNA Apr 2024 17.500 call finance.yahoo.com - March 16 at 8:32 AM
	VRNA Apr 2024 15.000 call finance.yahoo.com - March 16 at 3:31 AM
	Andrew Fisher Joins Verona Pharma as General Counsel globenewswire.com - March 4 at 2:00 AM
	Buy Rating Affirmed: Verona Pharma’s Promising Future with Ensifentrine and Expanding R&D Pipeline markets.businessinsider.com - March 1 at 1:10 PM
	Verona Pharma plc (NASDAQ:VRNA) Q4 2023 Earnings Call Transcript finance.yahoo.com - March 1 at 1:10 PM
	3 Healthcare Stocks That Have Outperformed Nvidia Since 2022 fool.com - March 1 at 8:45 AM
	Verona Pharma plc 2023 Q4 - Results - Earnings Call Presentation seekingalpha.com - February 29 at 11:18 AM
	Verona Pharma plc: Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update finanznachrichten.de - February 29 at 10:48 AM
	Verona Pharma PLC Reports Fourth Quarter and Full Year 2023 Financial Results finance.yahoo.com - February 29 at 10:48 AM
	Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update globenewswire.com - February 29 at 2:00 AM
	Verona Pharma earnings preview: what to expect markets.businessinsider.com - February 28 at 1:35 PM
	When Will Verona Pharma plc (NASDAQ:VRNA) Turn A Profit? finance.yahoo.com - February 25 at 12:52 PM
	Verona Pharma PLC ADR wsj.com - February 25 at 7:52 AM
	VRNA Mar 2024 15.000 put finance.yahoo.com - February 17 at 7:46 PM
	VRNA Jun 2024 30.000 call finance.yahoo.com - February 17 at 2:46 PM
	Verona Pharma: A Few Points From The Bull And Bear Case seekingalpha.com - February 15 at 5:55 PM
	Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update finance.yahoo.com - February 15 at 10:20 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Adicet Bio

NASDAQ:ACET

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

CTI BioPharma

NASDAQ:CTIC

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.

Kinnate Biopharma

NASDAQ:KNTE

Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.

Verona Pharma

NASDAQ:VRNA

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial